论文部分内容阅读
目的探讨罗格列酮对2型糖尿病合并冠心病患者的影响。方法选择我院2型糖尿病合并冠心病患者80例,上述患者随机分为观察组和对照组。对照组常规处理,观察组同时给予罗格列酮治疗。观察两组心血管事件发生情况。结果观察组心肌梗死、血运重建术、卒中发生率与对照组比较,差异无统计学意义(P>0.05)。观察组患者左室射血分数和每搏输出量均低于对照组、左室舒张末期内径高于对照组,差异有统计学意义(P<0.05)。观察组心功能2级以上患者所占比例高于对照组,差异有统计学意义(P<0.05)。结论罗格列酮没有增加2型糖尿病合并冠心病患者心血管发生率,但提高了患者充血性心力衰竭发生的风险性。
Objective To investigate the effect of rosiglitazone on type 2 diabetic patients with coronary heart disease. Methods Eighty patients with type 2 diabetes mellitus complicated with coronary heart disease in our hospital were randomly divided into observation group and control group. The control group routinely treated with rosiglitazone in the observation group. The incidence of cardiovascular events in both groups was observed. Results There was no significant difference in the incidence of myocardial infarction, revascularization and stroke between the observation group and the control group (P> 0.05). The left ventricular ejection fraction and stroke volume of observation group were lower than that of control group, and the diameter of left ventricular end-diastolic dimension was higher than that of control group (P <0.05). The proportion of patients with grade 2 or higher cardiac function in the observation group was higher than that in the control group, with significant difference (P <0.05). Conclusions Rosiglitazone did not increase the incidence of cardiovascular events in type 2 diabetic patients with coronary heart disease, but increased the risk of congestive heart failure.